Uncategorized files

Showing below up to 50 results in range #21,091 to #21,140.

• 
  Efavirenz, emtricitabine, and tenofovir disoproxil fumarate Table2.png 1,090 × 469; 28 KB
  
• 
  Efavirenz, emtricitabine, and tenofovir disoproxil fumarate Table3.png 1,092 × 429; 26 KB
  
• 
  Efavirenz, emtricitabine, and tenofovir disoproxil fumarate Table4.png 1,565 × 4,853; 1.26 MB
  
• 
  Efavirenz, emtricitabine, and tenofovir disoproxil fumarate Table5.png 1,555 × 2,893; 559 KB
  
• 
  Efavirenz, emtricitabine, and tenofovir disoproxil fumarate Table6.png 1,559 × 5,748; 1.01 MB
  
• 
  Efavirenz, emtricitabine, and tenofovir disoproxil fumarate Table7.png 1,092 × 443; 33 KB
  
• 
  Efavirenz, emtricitabine, and tenofovir disoproxil fumarate Table8.png 1,087 × 563; 46 KB
  
• 
  Efavirenz, emtricitabine, and tenofovir disoproxil fumarate Table9.png 1,091 × 324; 25 KB
  
• 
  EfavirenzStructure.png 224 × 140; 6 KB
  
• 
  Efavirenz AE Table1.png 639 × 1,607; 132 KB
  
• 
  Efavirenz AE Table2.png 614 × 506; 70 KB
  
• 
  Efavirenz Adult Clinical Study.png 519 × 644; 81 KB
  
• 
  Efavirenz Dosa Pediatrics.png 537 × 469; 52 KB
  
• 
  Efavirenz How Supplied.png 532 × 379; 60 KB
  
• 
  Efavirenz Lab AE Ad.png 505 × 694; 73 KB
  
• 
  Efavirenz Label.png 600 × 3,536; 255 KB
  
• 
  Efavirenz Structure.png 178 × 135; 15 KB
  
• 
  Efavirenz str.png 290 × 162; 7 KB
  
• 
  Efdfc0355363446eac868f3bf93ea0 jumbo.jpeg 728 × 1,024; 148 KB
  
• 
  Efepime2g.png 417 × 134; 88 KB
  
• 
  Effect of Atorvastatin on the Pharmacokinetics of Co-administered Drugs.PNG 1,100 × 269; 23 KB
  
• 
  Effect of LIPITOR on Cumulative Incidence of Non-Fatal MI or CHD Death.PNG 1,035 × 340; 43 KB
  
• 
  Effect of LIPITOR on Time to Occurrence of Major Cardiovascular Event.PNG 1,068 × 330; 52 KB
  
• 
  Effect of co-administered compounds on the PK of daridorexant.png 1,274 × 1,096; 454 KB
  
• 
  Effect of daridorexant on the PK of other compounds.png 1,250 × 1,086; 543 KB
  
• 
  Effect of smoking.png 1,041 × 147; 9 KB
  
• 
  Effectiveness of ocp.png 527 × 204; 8 KB
  
• 
  EffectsOfIncisionOnPPG-Large.png 800 × 567; 453 KB
  
• 
  Effects of Adempas in PATENT-1 on Events of Clinical Worsening (ITT analysis set).png 1,012 × 298; 35 KB
  
• 
  Effects of Adempas on the Change in WHO Functional Class in CHEST-1 from Baseline to Week 16.png 1,018 × 112; 21 KB
  
• 
  Effects of Adempas on the Change in WHO Functional Class in PATENT-1 from Baseline to Week 12.png 1,014 × 110; 22 KB
  
• 
  Effects of co-administered drugs.PNG 927 × 1,228; 97 KB
  
• 
  Effects of hepatic impairment and renal impairment on daridorexant PK.png 1,230 × 788; 248 KB
  
• 
  EffexorXR 75and150mg.png 909 × 1,018; 1.25 MB
  
• 
  Effexor NDC 00080833.jpg 1,024 × 781; 144 KB
  
• 
  Effexor NDC 00080836.jpg 1,024 × 781; 151 KB
  
• 
  Effexor NDC 00080837.jpg 640 × 480; 34 KB
  
• 
  Effexor NDC 675440189.jpg 640 × 480; 29 KB
  
• 
  Efficacy of Docetaxel in the Treatment of Breast Cancer Patients Previously Treated with an Alkylating-Containing Regimen.png 622 × 704; 63 KB
  
• 
  Efficacy of Docetaxel in the Treatment of Breast Cancer Patients Previously Treated with an Anthracycline-Containing Regimen.png 623 × 639; 65 KB
  
• 
  Effient.pdf ; 575 KB
  
• 
  Effient NDC 00025121.jpg 640 × 480; 28 KB
  
• 
  Effient NDC 00025123.jpg 640 × 480; 37 KB
  
• 
  EffusionsTreated.jpg 640 × 734; 278 KB
  
• 
  Efinaconazole Adv Eff.png 398 × 336; 30 KB
  
• 
  Efinaconazole CS.png 628 × 473; 50 KB
  
• 
  Efinaconazole Ing and App.png 623 × 1,225; 123 KB
  
• 
  Efinaconazole Ins for Use.png 631 × 1,547; 191 KB
  
• 
  Efinaconazole PDP.png 639 × 1,055; 399 KB
  
• 
  Efinaconazole Patient Pack.png 631 × 1,509; 189 KB